Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medeva plc

Executive Summary

Sales increase 39% to $120 mil. for the first half of 1993, Medeva reports Aug. 24. After-tax profit declines by 9% to $13 mil. due to interest charges and an increase in the estimated tax rate to 34% for the year. Medeva notes that the company is on track to meet its revised pre-tax profit figure of $67 mil. previously announced in July. Medeva had to revise the 1993 estimate downward from $82 mil. because of inventory overages at its U.S. subsidiary IMS and the two-week closing of MD Pharmaceutical, its methylphenidate manufacturing plant in the U.S., due to GMP problems.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS023227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel